Skip to main content

Table 1 Therapy profiles

From: HIV-1 mutational pathways under multidrug therapy

Therapy profiles

Compounds

N

Duration

# Previous

3TC AZT

259

549 (21,3515)

3 (0,28)

d4T DDI

149

553 (40,3291)

5.2 (0,19)

TDF FTC

123

284 (28,1122)

5.9 (0,25)

3TC d4T

115

646 (19,3508)

4.5 (0,18)

3TC TDF

96

311 (27,1360)

7.4 (0,20)

3TC DDI

61

590 (43,2268)

8.6 (1,37)

3TC ABC

52

397 (40,1140)

6.5 (0,18)

AZT

50

379 (1,1939)

2 (0,12)

3TC ABC AZT

50

437 (28,1423)

4.6 (0,19)

AZT DDI

49

413 (57,1408)

5.1 (0,17)

  1. The data in the current study contains 119 unique combinations of reverse transcriptease inhibitors. The 10 most common combinations are listed here, along with the number of subjects receiving them, mean (range) duration in days, and mean (range) number of previous therapies when administered. Note that these therapies may also have included protease inhibitors. The full table is given in the supplement.